Apollo Hospitals Enterprise (APOLLOHOSP) Weekly Analysis
Price & Volume
The stock price rose by 1.63% during the week ending June 5, 2026. Trading activity saw a decrease in volume compared to the previous week. The stock closed at 8310.0, maintaining a position above both its 50-day and 200-day moving averages.
Technicals
The market shows a positive trend with the price at 8310.0, sitting above both the 20-week and 50-week moving averages. The 20-week moving average, which tracks the average price over 20 weeks, and the 50-week moving average are both sloping upward. Momentum indicators are mixed, with the Relative Strength Index (RSI) at 61.83 indicating moderate strength, while the Moving Average Convergence Divergence (MACD) shows a bearish crossover. Volatility, measured by Bollinger Band width, has contracted to 6.04%, suggesting a period of reduced price range expansion compared to the previous week.
Fundamentals
Apollo Hospitals Enterprise reported strong recent performance with revenue up 18.1% year-over-year (YoY) and net profit surging 33.1% YoY in the Mar 2026 quarter. The operating margin stood at 15.0% for the quarter. The company currently trades at a Price-to-Earnings (PE) ratio of 79.5x and a Price-to-Book (PB) ratio of 12.0x. These metrics reflect recent growth and the company's market valuation.
News
During the week ending June 5, 2026, Apollo Hospitals Enterprise Ltd. experienced notable market activity, characterized by a rise to a 52-week high of Rs 8,417.5. The stock's technical performance was marked by a golden cross and a significant surge in open interest, drawing attention from various market analysts. In corporate developments, the company announced the resignation of its President of Group Oncology. These events collectively reflected a period of heightened investor interest and technical momentum for the healthcare provider, even as the firm navigated changes within its senior leadership team.
Events
Apollo Hospitals has scheduled a meeting of its secured creditors for June 24, 2026, to seek approval for its proposed composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech.
Apollo Hospitals Enterprise Limited announced the resignation of Mr. Dinesh Madhavan, President of Group Oncology and International, effective from the close of business hours on May 30, 2026.
Apollo Hospitals Enterprise Limited has published notices for NCLT-convened meetings of its creditors and equity shareholders scheduled for June 24, 2026, to consider and approve a composite scheme of arrangement involving its demerger and restructuring.
Apollo Hospitals Enterprise Limited has published notices for NCLT-convened meetings of its creditors and equity shareholders scheduled for June 24, 2026, to consider and approve a composite scheme of arrangement involving its subsidiaries.
Apollo Hospitals Enterprise Limited has released the transcript of its earnings call held on May 21, 2026, regarding the audited financial results for the quarter and year ended March 31, 2026.
Apollo Hospitals Enterprise Limited reported its financial results for the quarter and year ended March 31, 2026, highlighting consolidated revenue growth of 16% for Q4 FY26 and 13% for the full fiscal year. These results provide shareholders with a performance overview across its healthcare services, pharmacy distribution, and diagnostic segments.
Apollo Hospitals conducted a conference call in May 2026 to discuss operational performance and financial updates. The session provided shareholders with insights into the company's current business trajectory and strategic focus areas.
Apollo Hospitals Enterprise Limited has announced the divestment of its cradle and fertility businesses to Kids Clinic India Ltd for ₹1,550 crore and received board approval to merge its subsidiary, Apollo Hospitals North Limited, into the parent company. These strategic moves aim to simplify the business structure and enhance operational efficiency.
ICRA has issued a credit rating rationale report for the company, providing an assessment of its financial stability and debt repayment capacity for investors.
Apollo Hospitals Enterprise Limited announced the resignation of Mr. Dinesh Madhavan, President of Group Oncology and International, effective from the close of business hours on May 30, 2026.
Apollo Hospitals Enterprise Limited has published notices for NCLT-convened meetings of its creditors and equity shareholders scheduled for June 24, 2026, to consider and approve a composite scheme of arrangement involving its demerger and restructuring.
Apollo Hospitals Enterprise Limited has published notices for NCLT-convened meetings of its creditors and equity shareholders scheduled for June 24, 2026, to consider and approve a composite scheme of arrangement involving its subsidiaries.
Apollo Hospitals Enterprise Limited has released the transcript of its earnings call held on May 21, 2026, regarding the audited financial results for the quarter and year ended March 31, 2026.
Apollo Hospitals Enterprise Limited reported its financial results for the quarter and year ended March 31, 2026, highlighting consolidated revenue growth of 16% for Q4 FY26 and 13% for the full fiscal year. These results provide shareholders with a performance overview across its healthcare services, pharmacy distribution, and diagnostic segments.
Apollo Hospitals conducted a conference call in May 2026 to discuss operational performance and financial updates. The session provided shareholders with insights into the company's current business trajectory and strategic focus areas.
Apollo Hospitals Enterprise Limited has announced the divestment of its cradle and fertility businesses to Kids Clinic India Ltd for ₹1,550 crore and received board approval to merge its subsidiary, Apollo Hospitals North Limited, into the parent company. These strategic moves aim to simplify the business structure and enhance operational efficiency.
ICRA has issued a credit rating rationale report for the company, providing an assessment of its financial stability and debt repayment capacity for investors.
Weekly Snapshot
Highlights
- The stock rose by 1.63% this week, maintaining a position above its 50-day and 200-day moving averages despite a 19.76% decline in trading volume.
- Apollo Hospitals scheduled a meeting of secured creditors for June 24, 2026, to seek approval for its proposed composite scheme of arrangement.
- The company announced the resignation of Mr. Dinesh Madhavan, President of Group Oncology and International, effective May 30, 2026.
- Technical indicators show mixed signals with the RSI at 61.83 and a bearish MACD crossover, even as the price remains above key moving averages.
- Recent quarterly performance for Mar 2026 showed revenue growth of 18.1% YoY and a 33.1% YoY surge in net profit.
What This Means
The stock continues to exhibit a positive price trend, supported by its position above major moving averages. While trading volume has contracted, the company remains focused on its corporate restructuring efforts, specifically the upcoming NCLT-convened meetings for its composite scheme of arrangement. The recent leadership change in the Oncology division and the strong financial results from the March quarter provide a backdrop of operational transition and growth.
Latest Quarter Info
For the period ending March 2026, the company demonstrated robust revenue growth, with a significant 18.13% year-over-year increase, though quarter-over-quarter growth was more modest at 1.99%. Profitability trends show a strong upward trajectory, evidenced by a 33.09% year-over-year rise in net profit. The operating margin remained stable at 15.0%, indicating consistent operational efficiency. The mixed signals between QoQ and YoY performance suggest a healthy underlying business momentum with potential for sustained growth. Net profit also saw a positive quarter-over-quarter increase of 6.78%, reinforcing the positive profitability trend.